Major depressive disorder (MDD) is a common, disabling illness; approximately 300 million people are affected worldwide and around one-third of those with MDD meet criteria for treatment-resistant depression (TRD). TRD is commonly defined as failure to respond to at least two antidepressant treatments at therapeutic dose and duration and is associated with worse prognosis and greater economic costs. Established treatments for TRD with evidence of efficacy include ketamine/esketamine, adjunctive psychotherapy, electroconvulsive therapy and repetitive transcranial magnetic stimulation, but access to these interventions is limited.
Classic psychedelic compounds such as psilocybin were used in earlier eras of psychiatry and have re-emerged in modern clinical research. Psilocybin is metabolized to psilocin, a partial agonist at the 5-HT2A receptor; activation of serotonin receptors is linked to the characteristic subjective effects (heightened emotions, mystical-type experiences, altered perception, ego dissolution) that are hypothesized to underlie some therapeutic mechanisms.
The investigators conducted a two-arm, double-blind, randomized, placebo-controlled feasibility trial at one National Health Service (NHS) site in England. The primary objectives were feasibility-focused: recruitment, retention and estimation of variance on the Montgomery−Åsberg Depression Rating Scale (MADRS). A multilevel regression analysis was used with an intention-to-treat population to analyse outcomes. The trial included 6 weeks of follow-up after dosing.
Eligible participants met DSM-5 diagnostic criteria for major depressive disorder and had an inadequate response to at least two antidepressant treatments, or to one antidepressant plus one psychotherapy, consistent with common definitions of TRD. Sixty participants were randomized 1:1 to receive either 25 mg psilocybin or placebo. Randomization was balanced by age, sex and prior psilocybin exposure. According to the provided text, 59 of 60 participants completed MADRS assessments at all follow-up visits.
Participants received a single 25-mg dose of psilocybin or placebo in the context of a treatment package that included preparatory sessions, dosing support and post-dosing integration therapy. The trial therefore combined pharmacological administration with psychological support tailored to the psilocybin experience. Details on the exact content, number or duration of preparation/integration sessions and procedures for maintaining blinding were not fully reported in the provided excerpt.
Primary feasibility outcomes were recruitment and retention metrics and estimation of MADRS variance to inform future trials. Clinical efficacy outcomes reported in the excerpt include the adjusted between-group difference on MADRS at week 3, which favored the psilocybin arm by −10.41 (95% confidence interval −14.86 to −5.95) with a reported Cohen’s d of −1.70. This between-group advantage was sustained at week 6. Analyses were based on multilevel regression within an intention-to-treat framework.
Adverse events were recorded in both arms. The provided text reports 123 nonserious adverse events in the placebo arm and 164 in the psilocybin arm. The phase 1 randomized safety study previously conducted by the group (in healthy volunteers) reported no serious adverse events or adverse events leading to withdrawal, and no negative cognitive effects compared with placebo. In the present feasibility trial, the provided excerpt does not report whether any serious adverse events occurred, nor does it specify the nature, severity grading, duration, or relationship to study drug for the listed adverse events. Information about withdrawals for safety reasons, medical monitoring procedures, or prespecified stopping rules was not reported in the excerpt.
This trial builds on earlier open-label and randomized work in psilocybin therapy. Small open-label trials and phase 1 studies have suggested symptom improvements and acceptable safety signals in conditions including obsessive-compulsive disorder and TRD. Several single-arm and randomized trials in major depressive disorder (including non–treatment-resistant populations) and phase 2b trials in TRD have been completed internationally. Prior to this study, a single open-label, publicly funded pilot in England enrolled 20 patients with TRD. The authors state that, to their knowledge, this is the first randomized placebo-controlled feasibility trial of psilocybin for TRD specifically conducted within an NHS setting.
In this feasibility RCT, a single 25-mg dose of psilocybin given with psychological support produced a substantial adjusted reduction in MADRS scores versus placebo at week 3 that persisted to week 6. Recruitment and retention were sufficient to support feasibility objectives in this single-site NHS trial, and the observed MADRS variance and effect size are presented by the authors as supportive of a future confirmatory trial. The trial adds to the growing clinical literature suggesting potential efficacy of psilocybin-assisted therapy for TRD when delivered with structured psychological support.
The provided source text is truncated and does not include the full article. Specific operational details were not reported in the excerpt, including comprehensive descriptions of blinding procedures, exact numbers or types of preparatory and integration sessions, participant baseline characteristics beyond the balancing factors, longer-term outcomes beyond 6 weeks, full safety tables (including serious adverse events), concomitant medications management, or site-level implementation details. Where the excerpt lacked detail, those specifics were not inferred and are therefore not reported here.
Note: this summary is limited to information contained in the provided excerpt of the article; additional data and methodological details may be available in the full published paper.